Cumberland Pharmaceuticals Inc (CPIX) - Net Assets
Based on the latest financial reports, Cumberland Pharmaceuticals Inc (CPIX) has net assets worth $25.80 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($65.90 Million) and total liabilities ($40.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Cumberland Pharmaceuticals Inc (CPIX) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $25.80 Million |
| % of Total Assets | 39.15% |
| Annual Growth Rate | 7.0% |
| 5-Year Change | -51.9% |
| 10-Year Change | -70.65% |
| Growth Volatility | 73.1 |
Cumberland Pharmaceuticals Inc - Net Assets Trend (2005–2024)
This chart illustrates how Cumberland Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore CPIX total assets for the complete picture of this company's asset base.
Annual Net Assets for Cumberland Pharmaceuticals Inc (2005–2024)
The table below shows the annual net assets of Cumberland Pharmaceuticals Inc from 2005 to 2024. For live valuation and market cap data, see how much is Cumberland Pharmaceuticals Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $22.55 Million | -22.95% |
| 2023-12-31 | $29.26 Million | -18.66% |
| 2022-12-31 | $35.97 Million | -15.56% |
| 2021-12-31 | $42.60 Million | -9.11% |
| 2020-12-31 | $46.87 Million | -8.24% |
| 2019-12-31 | $51.09 Million | -8.07% |
| 2018-12-31 | $55.57 Million | -13.06% |
| 2017-12-31 | $63.92 Million | -12.58% |
| 2016-12-31 | $73.12 Million | -4.82% |
| 2015-12-31 | $76.82 Million | -4.87% |
| 2014-12-31 | $80.75 Million | +1.84% |
| 2013-12-31 | $79.29 Million | -7.33% |
| 2012-12-31 | $85.57 Million | +3.30% |
| 2011-12-31 | $82.84 Million | +6.59% |
| 2010-12-31 | $77.72 Million | +7.61% |
| 2009-12-31 | $72.22 Million | +311.40% |
| 2008-12-31 | $17.55 Million | +4.83% |
| 2007-12-31 | $16.75 Million | +50.52% |
| 2006-12-31 | $11.13 Million | +78.48% |
| 2005-12-31 | $6.23 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cumberland Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1220355600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $46.82 Million | 204.88% |
| Total Equity | $22.85 Million | 100.00% |
Cumberland Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Cumberland Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Flanigans Enterprises Inc
NYSE MKT:BDL
|
$58.55 Million |
|
Monalisa
KO:012690
|
$58.60 Million |
|
Namhwa Industrial Co. Ltd
KQ:111710
|
$58.60 Million |
|
Mesa Air Group Inc
NASDAQ:MESA
|
$58.63 Million |
|
Eltek Ltd
NASDAQ:ELTK
|
$58.46 Million |
|
Theralase Technologies Inc.
V:TLT
|
$58.45 Million |
|
Scilex Holding Company
NASDAQ:SCLX
|
$58.44 Million |
|
Anson Resources Ltd
AU:ASN
|
$58.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cumberland Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 29,603,441 to 22,853,494, a change of -6,749,947 (-22.8%).
- Net loss of 6,479,770 reduced equity.
- Share repurchases of 579,049 reduced equity.
- Other factors increased equity by 308,872.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.48 Million | -28.35% |
| Share Repurchases | $579.05K | -2.53% |
| Other Changes | $308.87K | +1.35% |
| Total Change | $- | -22.80% |
Book Value vs Market Value Analysis
This analysis compares Cumberland Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.68x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 11.25x to 2.68x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $0.39 | $4.36 | x |
| 2006-12-31 | $0.68 | $4.36 | x |
| 2007-12-31 | $1.01 | $4.36 | x |
| 2008-12-31 | $1.06 | $4.36 | x |
| 2009-12-31 | $3.96 | $4.36 | x |
| 2010-12-31 | $3.69 | $4.36 | x |
| 2011-12-31 | $4.03 | $4.36 | x |
| 2012-12-31 | $4.33 | $4.36 | x |
| 2013-12-31 | $4.33 | $4.36 | x |
| 2014-12-31 | $4.51 | $4.36 | x |
| 2015-12-31 | $4.50 | $4.36 | x |
| 2016-12-31 | $4.51 | $4.36 | x |
| 2017-12-31 | $4.03 | $4.36 | x |
| 2018-12-31 | $3.58 | $4.36 | x |
| 2019-12-31 | $3.32 | $4.36 | x |
| 2020-12-31 | $3.10 | $4.36 | x |
| 2021-12-31 | $2.87 | $4.36 | x |
| 2022-12-31 | $2.49 | $4.36 | x |
| 2023-12-31 | $2.07 | $4.36 | x |
| 2024-12-31 | $1.63 | $4.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cumberland Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17.11%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 3.31x
- Recent ROE (-28.35%) is below the historical average (1.56%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 31.35% | 18.28% | 1.05x | 1.63x | $1.33 Million |
| 2006 | 39.59% | 24.72% | 0.67x | 2.38x | $3.29 Million |
| 2007 | 24.15% | 14.41% | 0.97x | 1.73x | $2.37 Million |
| 2008 | 27.15% | 13.59% | 1.13x | 1.77x | $3.01 Million |
| 2009 | 4.28% | 7.10% | 0.42x | 1.44x | $-4.13 Million |
| 2010 | 3.16% | 5.36% | 0.50x | 1.18x | $-5.32 Million |
| 2011 | 6.82% | 11.06% | 0.54x | 1.15x | $-2.64 Million |
| 2012 | 6.82% | 11.96% | 0.50x | 1.15x | $-2.73 Million |
| 2013 | -2.65% | -6.57% | 0.37x | 1.10x | $-10.05 Million |
| 2014 | 3.00% | 6.57% | 0.39x | 1.18x | $-5.65 Million |
| 2015 | 0.95% | 2.18% | 0.36x | 1.20x | $-6.96 Million |
| 2016 | -1.29% | -2.86% | 0.35x | 1.28x | $-8.27 Million |
| 2017 | -12.44% | -19.39% | 0.44x | 1.45x | $-14.39 Million |
| 2018 | -12.47% | -17.09% | 0.36x | 2.02x | $-12.55 Million |
| 2019 | -6.92% | -10.29% | 0.33x | 2.05x | $-8.65 Million |
| 2020 | -7.11% | -8.92% | 0.39x | 2.05x | $-8.04 Million |
| 2021 | -8.19% | -9.75% | 0.43x | 1.97x | $-7.79 Million |
| 2022 | -15.36% | -13.26% | 0.45x | 2.56x | $-9.20 Million |
| 2023 | -21.21% | -15.88% | 0.48x | 2.76x | $-9.24 Million |
| 2024 | -28.35% | -17.11% | 0.50x | 3.31x | $-8.77 Million |
Industry Comparison
This section compares Cumberland Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $236,113,024
- Average return on equity (ROE) among peers: -47.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cumberland Pharmaceuticals Inc (CPIX) | $25.80 Million | 31.35% | 1.55x | $58.49 Million |
| Aurora Cannabis Inc (ACB) | $602.92 Million | -11.50% | 0.39x | $197.35 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $340.21 Million |
| Alkermes Plc (ALKS) | $54.20 Million | -73.99% | 0.03x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $1.77 Billion |
| Amphastar P (AMPH) | $639.42 Million | 21.51% | 1.37x | $959.02 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -104.36% | 9.57x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $344.93 Million | 26.40% | 10.61x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $287.08 Million | 1.44% | 0.21x | $199.00 Million |
| ANI Pharmaceuticals Inc (ANIP) | $40.96 Million | 0.73% | 0.09x | $1.80 Billion |
About Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fe… Read more